Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Nature Medicine

Volumn 21, Issue 7, 2015, Pages 795-801

  Siravegna, Giulia ^a,b,c   Mussolin, Benedetta ^b   Buscarino, Michela ^b   Corti, Giorgio ^b   Cassingena, Andrea ^d   Crisafulli, Giovanni ^b   Ponzetti, Agostino ^e   Cremolini, Chiara ^f   Amatu, Alessio ^d   Lauricella, Calogero ^d   Lamba, Simona ^b   Hobor, Sebastijan ^b,j   Avallone, Antonio ^g   Valtorta, Emanuele ^d   Rospo, Giuseppe ^b   Medico, Enzo ^a,b   Motta, Valentina ^d   Antoniotti, Carlotta ^f   Tatangelo, Fabiana ^g   Bellosillo, Beatriz ^h   Veronese, Silvio ^d   Budillon, Alfredo ^g   Montagut, Clara ^h   Racca, Patrizia ^e   Marsoni, Silvia ^b   Falcone, Alfredo ^f   Corcoran, Ryan B ⁱ   Di Nicolantonio, Federica ^a,b   Loupakis, Fotios ^f   Siena, Salvatore ^d   Sartore Bianchi, Andrea ^d   Bardelli, Alberto ^a,b   more..

^a UNIVERSITY OF TURIN   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d OSPEDALE NIGUARDA CA GRANDA   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f UNIVERSITY HOSPITAL OF PISA   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h HOSPITAL DEL MAR   (Spain)

ⁱ MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^j IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; CIRCULATING TUMOR DNA; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RALTITREXED; TIPIRACIL; UNCLASSIFIED DRUG; ANTIBODY; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CLONAL EVOLUTION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG SENSITIVITY; DYNAMICS; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; ERBB2 GENE; FLT3 GENE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; LETTER; MAJOR CLINICAL STUDY; MAP2K1 GENE; MET GENE; ONCOGENE K RAS; ONCOGENE N RAS; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ALLELE; ANTAGONISTS AND INHIBITORS; BLOOD; CELL CLONE; COLORECTAL NEOPLASMS; DRUG RESISTANCE; GENETICS; IMMUNOLOGY; MUTATION; PATHOLOGY;

ALLELES; ANTIBODIES; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CLONAL EVOLUTION; CLONE CELLS; COLORECTAL NEOPLASMS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84936748494     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3870     Document Type: Letter

References (49)

1. Wong, N.A. et al. RAS testing of colorectal carcinoma - a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group. J. Clin. Pathol. 67, 751-757 (2014).
2. Douillard, J.Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
3. Di Nicolantonio, F. et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin. Oncol. 26, 5705-5712 (2008).
4. Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673 (2013).
5. Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523 (2011).
6. Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
7. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
8. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
9. De Mattos-Arruda, L. et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann. Oncol. 25, 1729-1735 (2014).
10. Overman, M.J. et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J. Clin. Oncol. 31, 17-22 (2013).
11. Diaz, L.A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579-586 (2014).
12. Siravegna, G. & Bardelli, A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol. 15, 449 (2014).
13. Fleischhacker, M. & Schmidt, B. Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta. 1775, 181-232 (2007).
14. Schwarzenbach, H., Hoon, D.S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426-437 (2011).
15. Misale, S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486, 532-536 (2012).
16. Diaz, L.A. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486, 537-540 (2012).
17. Reinert, T. et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut. (2015).
18. Sanmamed, M.F. et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin. Chem. 61, 297-304 (2015).
19. Diehl, F. et al. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat. Methods 3, 551-559 (2006).
20. Hindson, B.J. et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal. Chem. 83, 8604-8610 (2011).
21. Bardelli, A. & Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254-1261 (2010).
22. Misale, S., Di Nicolantonio, F., Sartore-Bianchi, A., Siena, S. & Bardelli, A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 4, 1269-1280 (2014).
23. Palacio-Rúa, K.A., Isaza-Jiménez, L.F., Ahumada-Rodríguez, E. & Muñetón-Peña, C.M. Genetic analysis in APC, KRAS, and TP53 in patients with stomach and colon cancer. Rev. Gastroenterol Mex. 79, 79-89 (2014).
24. Network, C.G.A. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
25. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
26. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal 6, pl1 (2013).
27. Beaver, J.A. et al. Detection of cancer DNA in plasma of early stage breast cancer patients. Clin. Cancer Res. (2014).
28. Montagut, C. et al. Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer. in ASCO Vol. abstr 3526 (2014).
29. Arena, S. et al. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin. Cancer Res. (2015).
30. Mohan, S. et al. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet. 10, e1004271 (2014).
31. Valtorta, E. et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int. J. Cancer 133, 1259-1265 (2013).
32. Hata, A. et al. Panitumumab rechallenge in chemorefractory patients with metastatic colorectal cancer. J. Gastrointest. Cancer 44, 456-459 (2013).
33. Misale, S. et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to Anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 6, 224ra226 (2014).
34. Morelli, M.P. et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann. Oncol. (2015).
35. Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra224 (2014).
36. Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255 (2013).
37. Seghers, A.C., Wilgenhof, S., Lebbé, C. & Neyns, B. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 22, 466-472 (2012).
38. Hata, A., Katakami, N., Kaji, R., Fujita, S. & Imai, Y. Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J. Thorac. Oncol. 8, e27-29 (2013).
39. Nakamura, T. et al. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J. Thorac. Oncol. 7, 1369-1381 (2012).
40. Eisenhauer, E.A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009).
41. Ma, E.S., Wong, C.L., Law, F.B., Chan, W.K. & Siu, D. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J. Clin. Pathol. 62, 886-891 (2009).
42. Tiacci, E. et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 119, 192-195 (2012).
43. Gonzalez de Castro, D. et al. A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens. Br. J. Cancer 107, 345-351 (2012).
44. Sundström, M. et al. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer 10, 660 (2010).
45. Hayden, R.T. et al. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. J. Clin. Microbiol. 51, 540-546 (2013).
46. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589-595 (2010).
47. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
48. Forbes, S.A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic. Acids. Res. (2014).
49. Ye, K., Schulz, M.H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865-2871 (2009).